Outcome of Board Meeting held on Friday, 14th November, 2025 to approve the unaudited Financial Statement for the Quarter and Half year ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Phaarmasia Ltd's board met on 14 November 2025 via video conference and approved the unaudited financial results for the quarter and half-year ended 30 September 2025. The board also took on record the Limited Review Report for the period, noted the CEO/CFO compliance certificate under SEBI LODR, reviewed related party transactions, and discussed general business operations. The filing is a standard regulatory disclosure under SEBI Listing Regulations and does not include the actual financial numbers in this document.
Routine procedural disclosure with no material business action announced. Shareholders should wait for the detailed financial results to assess actual revenue, profit, and margin performance for the quarter.